Hanna Hogan
Family · Inverness, FLNPI 1457869927
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,475 and has fallen 89.7% since, to $152 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$519
- GSK$351
- Amarin Pharma, Inc.$340
- AbbVie$283
- Sunovion Pharmaceuticals Inc.$216
- Novartis$188
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,835100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $519 |
| GSK | 24 | $351 |
| Amarin Pharma, Inc. | 17 | $340 |
| AbbVie | 13 | $283 |
| Sunovion Pharmaceuticals Inc. | 10 | $216 |
| Novartis | 10 | $188 |
| Johnson & Johnson | 6 | $184 |
| Bayer | 8 | $167 |
| AstraZeneca | 10 | $166 |
| Boehringer Ingelheim | 5 | $91 |
| Lilly USA, LLC | 5 | $83 |
| Astellas Pharma US Inc | 4 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $75 |
| Corcept Therapeutics | 3 | $74 |
| Boston Scientific | 2 | $74 |
| Amgen | 5 | $73 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Biogen | 4 | $66 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Sumitomo Pharma America, Inc. | 4 | $62 |
| Xeris Pharmaceuticals, Inc. | 4 | $60 |
| Pfizer | 3 | $54 |
| Nestle Healthcare Nutrition Inc. | 3 | $53 |
| Abbott | 3 | $51 |
| Sun Pharmaceutical Industries Inc. | 2 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| Dexcom, Inc. | 2 | $46 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Evoke Pharma, Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Inogen, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$110
How this compares
$3,835 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $21,459 |
| TrulicityDulaglutide | 11 | $11,383 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 127 | $10,108 |
| AptiomEslicarbazepine Acetate | 15 | $9,528 |
| XareltoRivaroxaban | 18 | $8,840 |
| MovantikNaloxegol Oxalate | 30 | $7,710 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,160 |
| MyrbetriqMirabegron | 14 | $3,180 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $2,734 |
| Divalproex Sodium | 14 | $1,508 |
| Potassium Chloride | 41 | $1,427 |
| Midodrine Hcl | 21 | $1,289 |
| Bumetanide | 19 | $842 |
| Lisinopril | 54 | $808 |
| Atorvastatin Calcium | 66 | $780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $54 | $21,45966 claims |
| Lilly USA, LLCTrulicity | $83 | $11,38311 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $216 | $9,52815 claims |
| Johnson & JohnsonXarelto | $184 | $8,84018 claims |
| GSKTrelegy Ellipta | $351 | $7,16012 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $3,18014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Inverness
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.